Microbiologist with expertise on the molecular mechanisms by which persistent pathogens modulate human gene expression, metabolism and immunity. Serves as PolyBio’s President, Research Director, and on the Board of Directors. Amy is an expert in conceptualizing and coordinating large-scale collaborative research projects. She has written multiple review articles that delineate core biological drivers of the LongCovid and ME/CFS disease processes. She holds a Bachelor of Science in biology from Georgetown University and a PhD in microbiology from Murdoch University in Australia.

Assistant Professor in the Division of Neurotherapeutics at Harvard University and a neuroimmunologist with expertise in persistent central nervous system consequences. Mike uses functional and structural imaging techniques to identify abnormal patterns in brain inflammation and metabolism in patients with infection-associated chronic disease. He facilitates collaboration among PolyBio research teams and serves on the Board of Directors. He received a master’s degree in behavioral neuroscience at the University of Colorado and a PhD in experimental clinical psychology at Tufts University.

Mission-driven executive with 20+ years leading innovation at the intersection of science, strategy, and systems change. Serves as PolyBio’s Chief Operations & Innovation Officer, working with the CEO and Board to drive the Foundation’s strategic growth and operational excellence. Deep expertise in scaling organizations, forging cross-sector partnerships, and turning bold ideas into impact at organizations including Physicians for Human Rights, Oxfam America, and Good Jobs Institute. She holds a BA in Social Studies from Harvard University and an MBA with a focus on sustainable operations from the MIT Sloan School of Management.

Instructor in the Neurology Department of Massachusetts General Hospital & Harvard Medical School. Innovator of experimental models for the study of amyloid biology and infection in neurodegenerative disease. His current research focuses on characterizing amyloid’s activity as an antimicrobial peptide that forms in response to viral and bacterial pathogens. William holds a PhD in Neuroscience from Northwestern University and completed postdoctoral work on genetics & Alzheimer’s disease biology at Harvard University.

Clinician-scientist determined to map inflammatory signatures specific to the microbiome in a creative fashion. Also an oral surgeon, Professor of Genomic Medicine, and member of the J. Craig Venter Institute infectious disease department. Life prior to disease is his mantra! Marcelo holds a DDS from College of Dentistry, Campos, Rio de Janeiro, a PhD in Craniofacial Molecular Biology from University of Southern California, and a DMedSc in Oral Medicine and Infectious Diseases from Harvard University.

CRISPR-Cas system discovery specialist at Mammoth Biosciences with a passion for developing & using technologies to identify novel genes from big data. Co-founder & Head of Bioinformatics at Ancilia Therapeutics focused on bacteriophage genomics and microbiome. Also an affiliate at the Lawrence Berkeley National Lab, Joint Genome Institute. David holds a Ph.D. in synthetic and molecular biology and biochemistry techniques from the CNB-CSIC in Madrid, Spain, and completed a postdoctoral position at UC Berkeley on metagenomics.

Scientist at the Max-Planck-Institute for Biology of Ageing working to understand how cellular organelles sense and respond to intracellular pathogens. Expert in mitochondrial dynamics, parasite biology, and immunometabolism. Lena holds a PhD in microbiology & immunology from Stanford University and completed postdoctoral research on the biology of infection at the University of Padua, Italy.

Currently a Senior Advisor to ArcLight Capital Partners and a Board member of TransMontaigne Partners, Francis has thirty years of experience in the planning, design, investment and governance of commodity related infrastructure businesses.  He was previously a Director of Investments at Vitol, Executive Director of Morgan Stanley and Project Manager at AECOM.  Francis holds an MBA from the University of Michigan and a Bachelor of Science in Civil Engineering from the University of Wisconsin-Platteville.

Expert with nearly 10 years’ experience in the legal field, focusing on private equity and corporate law. Serves as Senior Director and Head of the Legal, Americas at Gordon Brothers, where he oversees the firm’s front-line transactional counsel primarily for the Brands, Real Estate and Valuations practices. Advises on legal strategy, transaction strategy and negotiation, corporate governance, and corporate development opportunities. John holds a Juris Doctor from Georgetown University Law Center and a Bachelor of Arts from Tufts University.

Over 15 years of experience in the private equity and investment banking industries. He is currently a Partner at Newlight Partners, where he focuses on investments in power and infrastructure. Prior to joining Newlight he worked as Managing Director to its predecessor, the Strategic Investments Group of Soros Fund Management, as an Investment Banking Analyst for Bear Stearns, and as an Analyst for the Royal Bank of Scotland. Mark holds a Bachelor in Science and Foreign Service in International Economics from Georgetown University.

Pediatric infectious disease physician with expertise in Lyme disease and HIV/AIDS. Charlotte worked at Boston Children’s Hospital Division of Infectious Diseases and the Dean Center for Tickborne Illness at Spaulding Rehabilitation Hospital. She is passionate about translating research on Borrelia burgdorferi and related vector-borne pathogens into cutting-edge clinical care. Charlotte received her medical degree from Harvard Medical School and did residency and infectious disease fellowship training at Boston Children’s Hospital. She also serves on PolyBio’s Board of Directors.

Founder and CEO of TLDM Technologies, a New York-based deep tech company working to reduce preventable foodborne illness. Jessica previously was an executive at Glossier Inc. and a management consultant at Bain & Company. She serves on the advisory board of Mount Sinai’s Department of Rehabilitation, and works on Long COVID research at Mount Sinai’s CoRE Clinic. Jessica holds a degree from the Wharton School of Business, where she focused on Food Marketing and Biotechnology.